New Age Alpha Advisors’s Sarepta Therapeutics SRPT Stock Holding History

New Age Alpha Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595K	Buy	+33,083	New	+$626K	0.03%	580
2025 Q4	–	Sell	-39,472	Closed	-$761K	–	910
2025 Q3	$761K	Sell	39,472 -919	-2%	-$16.4K	0.03%	451
2025 Q2	$691K	Buy	40,391 +21,049	+109%	+$898K	0.03%	453
2025 Q1	$1.23M	Sell	19,342 -50,998	-73%	-$5.37M	0.06%	403
2024 Q4	$8.55M	Buy	+70,340	New	+$8.62M	0.35%	69

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

New Age Alpha Advisors's SRPT Position: Q2 2026 in Review

New Age Alpha Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 33,083 shares worth $595K. The stake represents 0.03% of the portfolio and ranks #580 among its holdings. This is a return to the name: New Age Alpha Advisors previously reported a position in SRPT as recently as Q3 2025.

New Age Alpha Advisors first reported a position in SRPT in Q4 2024 and has held it in 5 quarters since. The position peaked at $8.55M in Q4 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

New Age Alpha Advisors held 33,083 shares of Sarepta Therapeutics worth $595K as of Q2 2026.
Sarepta Therapeutics was a new New Age Alpha Advisors position in Q2 2026.
Sarepta Therapeutics made up 0.03% of New Age Alpha Advisors's portfolio in Q2 2026, its #580 holding.
New Age Alpha Advisors first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 5 quarters since.
New Age Alpha Advisors's Sarepta Therapeutics position peaked at $8.55M in Q4 2024.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.